Drug Profile
B-cell maturation antigen CAR-T cell therapy - Innovative Cellular Therapeutics
Latest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator Innovative Cellular Therapeutics
- Developer Henan Cancer Hospital; Innovative Cellular Therapeutics
- Class CAR-T cell therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in China
- 01 Dec 2017 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in China (unspecified route) (ChiCTR1800014955)